平特五不中

• Up to $200,000 for 18 months.
• Funding is non-renewable.
• Note: The Accelerate grant requires direct financial support from (a) commercial partner(s) or foundations. The total of the third-party contribution(s) must match HBHL鈥檚 contribution at a rate of at least 1:1. In-kind support is not considered a contribution to this requirement.

Prerequisites:

• A Report of Invention (ROI) must have been filed with the Innovation and Partnerships Office at 平特五不中 (I+P).
• To be eligible for HBHL鈥檚 Accelerate Grants, applicants must have聽received approval from the HBHL Innovation Committee (IC) to apply to the Accelerate phase.

1. Invitation to apply

To be eligible for HBHL鈥檚 Accelerate Grants, applicants must have either a) successfully fulfilled all of the requirements of the Ignite phase and received approval from the HBHL Innovation Committee and NeuroSphere team to apply to the accelerate phase, or b) met with the NeuroSphere staff (including the Entrepreneur in Residence) to discuss the proposed project in depth to determine its suitability, in addition to receiving approval from the HBHL Innovation Committee to apply to the Accelerate phase.

2. Eligibility review

The NeuroSphere team will assess the eligibility of applications based on the following criteria:

Applicant Eligibility

• Applicant: The applicant must be a 平特五不中 researcher who is eligible to hold Tri-Agency research funding (students and postdoctoral researchers are not eligible).
• Co-applicants: Co-applicants must be researchers from 平特五不中 or from one of HBHL鈥檚 CFREF partner institutions (Western University, Universit茅 de Montr茅al, University of British Columbia or Montr茅al Polytechnique). Grant funding may NOT be transferred to co-applicants from other institutions than the ones previously listed.
• Partners: This grant requires (a) commercial partner(s) or (b) foundation(s), interested in the commercialization of the technology, to match the HBHL contribution at a rate of at least 1:1.

Notes:

• This matching contribution must be a cash investment. While in-kind contributions are welcome and will be considered during the evaluation process, they will not be considered during assessment of this eligibility criteria.

• If the identified partner is a foundation, its eligibility will be evaluated by the NeuroSphere team on the basis that it is a real partner actively engaged in investing. Funding from foundation grants/awards will not be considered in meeting this eligibility requirement unless approved by the IC and NeuroSphere.听

• A letter of support from the commercial partner(s) confirming their financial commitment will be required as part of the Accelerate Grant application (the total amount listed must match the HBHL contribution). This letter must be for the full amount of funding, however the NeuroSphere team may allow 50% of the funding to be transferred up front and 50% at the project's mid-point. In such cases, HBHL instalments will be aligned with those of the partners.

• 平特五不中 will charge a 27% overhead rate on the partner(s) total cash contribution(s).

Intellectual Property

• A Report of Invention (ROI) must have been approved by 平特五不中鈥檚聽Innovation and Partnerships Office聽(I+P) and the technology must be active with I+P. If a 平特五不中 affiliated researcher decides to manage IP by themselves, without I+P, they will not be eligible. Even if projects adhere to guiding principles of Open Science, an ROI must be filed.
• A research agreement must be negotiated between 平特五不中 and the partners before the HBHL funds will be released, and must include a description of the agreements negotiated, including terms of access to intellectual property, licensing, and contractual arrangements, as applicable.

Allowable Costs

Funding must go towards direct support of technology maturation (i.e., personnel, materials and supplies). Business case and model evaluation, as well as strategic planning, may also be considered as allowable costs.

Equipment is not an eligible expense. Other ineligible expenses include market studies, patent searches or filling, maintenance costs or salaries associated with commercial development. Although these activities are not eligible, I+P and NeuroSphere staff can provide assistance in these areas.

Application Completeness: See table below

The NeuroSphere team is available to provide assistance with the application.

3. Peer Review

Once the application鈥檚 eligibility and relevance has been validated, a peer review committee will be formed to review the scientific excellence and commercialization potential of the application based on the following criteria:

• Quality of the development plan
  • Progress made during the Ignite phase and current status of the research and technology to be developed; and
  • Quality of the development plan and capacity to meet objectives and milestones;
• Potential for impact
  • Evidence of market need;
  • Commercial potential of the technology;
  • Competitiveness of the technology; and
  • Feasibility of the proposed objectives and timeline.
• Likelihood of success
  • Identification of potential hurdles in the research plan and plans for mitigation;
  • Relevance of milestones to commercialization plan;
  • Qualifications and track record of the applicants to achieve the results described; and
  • Quality of the medium- and long-term business plan.
• Budget
  • Appropriateness of the proposed budget to achieve the aims described; and
  • Appropriateness of contributions from industry partners and collaborators to support the aims of the project.
• SGBA+
  • Appropriateness of the application鈥檚 integration of sex as a biological variable, gender as a socio-cultural determinant of health, and/or other relevant factors (e.g., race, age, Indigeneity, ability) or an evidence-based justification for not including these or other intersectional factors.
  • Note that the historical omission of sex, gender and other identity factors from health research has resulted in a dearth of evidence about the effects of these factors. Therefore, a lack of evidence indicating the importance of these factors in the literature is not a sufficient justification on its own for omitting them in the proposed study.
  • Note that SGBA+ will be reviewed separately by designated, knowledgeable reviewers for all applications. Applicants may be asked to revise this section prior to receiving funding if reviewers deem it inadequate.

4. Strategic Selection and Final Approval

Upon completion of the peer review, the NeuroSphere staff will submit the application to the HBHL Innovation Committee for final decision and approval. To reach a funding decision, the HBHL Innovation Committee will consider both the results of the peer review as well as the strategic investment value of the application in contributing to HBHL鈥檚 innovation objectives (e.g., remaining funding, priority areas, continued support to promising existing projects, etc.).

5. Results and Post-Awards

• All applicants will be notified by email of the results of their application.
• Successful applicants will be sent a Notice of Award. It is the applicant鈥檚 responsibility to complete the Acceptance of Award form and other required documents, including the 平特五不中 Office of Sponsored Research (OSR) checklist, by the indicated date.
• Project start date must occur after the award has been approved.

6. Responsibilities of Successful Applicants

Successful applicants are required to:

• Spend all awarded funds within the granting period鈥攏o extensions will be permitted except in extremely extenuating circumstances;
• Provide a final report to retain access to all other HBHL funding programs, including the Neuro-Partnerships Program in collaboration with CQDM and MEDTEQ.
• Meet with the NeuroSphere business development team at the mid-point of the granting period to review progress and adjust the strategy if needed.
• Funded researchers, their collaborators and trainees are also encouraged to attend educational, training and entrepreneurship events/ workshops offered by NeuroSphere.

Access the Accelerate Proposal template (upload as part of single PDF application package).

In a maximum of 10 pages, describe the research project for which funding is requested. Refer to the evaluation criteria. Number the pages and indicate the Applicant鈥檚 name in the top right corner of each page. The Research Project should contain the following sections (with required space limitations):

1. Overview (1 page) Description of the technology/invention.

• Description of the business opportunity, medical and market need.
• Value proposition and justification on how the requested funds will contribute to help materialize the opportunity and advance the technology/invention readiness for commercial success.

2. R&D Technical Plan (5 to 6 pages)

• Background and context of the technology/invention.
• Synopsis of pertinent literature.
• Benefits and limitations of the technology/invention.
• Description of technical/scientific requirements to move the technology/invention and how the R&D plan would allow to address these requirements and facilitate the transition towards maturation/commercialization.
• A description of R&D expertise and experimental plan.
• Timelines, milestones and deliverables as well as an experimental risk mitigation strategy.
• Sex- and Gender-based Analysis Plus: Describe how sex as a biological variable, gender as a socio-cultural determinant of health and/or other relevant factors (e.g. race, age, Indigeneity, ability) have been considered in the research so far and how they will be integrated into the work going forward (if applicable). If none of the above factors were considered, provide an evidence-based justification for this decision. The applicant must attach to the application an electronic certificate of completion, showing their name and date completed, from at least one of .

3. Maturation/Commercialization Plan (2.5 to 3.5 pages)

• Value proposition, Targeted market(s) and best choice of receptor(s)/end-user(s).
• SWOT analysis.
• IP portfolio/Status and IP Strategy (open science applications will need to provide alternate IP strategy)
• Business expertise and choice of co-funding partner.
• Regulatory strategy.
• Best path for technology/invention to reach receptor(s)/end-user(s) (licensing, spin-off company or other course of action).
• Description of business development efforts already done.
• Opinions of Key Opinions Leaders and of potential partners if available.
• Timeline, milestones and deliverables necessary for the execution of the Maturation/Commercialization Plan.
• Description of the follow-on activities post funding period.
• Description of how the technology/invention is expected to solve identified medical need and expected socio-economic and health benefits to Canada.

4.听EDI (1/2 page): Should include:

鈥� Describe the manner in which the activities of your research team, and the teams) of any collaborators, advance 平特五不中's commitment to Equity, Diversity, & Inclusion (EDI). View examples of practices聽of practices that you can implement in your research design if you have not done so already.

Applicant must include all the necessary information (including tables, figures and a list of references) within 5 pages.

Please note that extra pages will be removed from your application.

When completing the EDI sections of the application for HBHL Start-up Funds, applicants must protect the privacy and confidentiality of others. How an individual self-identifies is considered personal and confidential information and should not be disclosed without that person鈥檚 consent.

Please do not include in your response any demographic information (e.g. gender, Indigeneity, ability, race, ethnicity and/or sexual orientation).

Instead, give concrete examples of clear and specific initiatives and measures that you and your team have undertaken. Examples of practises you may wish to refer to in your response are provided on the .

Access the Accelerate Budget template (upload as part of single PDF application package)

(Upload as part of single PDF application package)

Application PDF package must include an electronic certificate of completion (incl. name and date) from at least one of CIHR鈥檚